An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

NCT06021054 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease

Interventions

DRUG: Veligrotug (VRDN-001)
DRUG: Placebo

Sponsor

Viridian Therapeutics, Inc.